-
Posted by
Two Blokes Jun 9 -
Filed in
Stock
-
2 views
Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i.
